Related Experiment Video
Updated: Jun 3, 2025
Tissue Collection and RNA Extraction from the Human Osteoarthritic Knee Joint
Published on: July 22, 2021
Transcriptomic analysis of human cartilage identified potential therapeutic targets for hip osteoarthritis
Jingyi Huang1, Ming Liu1, Andrew Furey2
1Human Genetics & Genomics, Division of BioMedical Sciences, Faculty of Medicine, Memorial University of Newfoundland, 300 Prince Philip Drive, St. John's, Newfoundland & Labrador, A1B 3V6, Canada.
Abstract:
Cartilage degradation is the hallmark of osteoarthritis (OA). The purpose of this study was to identify and validate differentially expressed genes (DEGs) in human articular cartilage that could serve as potential therapeutic targets for hip OA. We performed transcriptomic profiling in a discovery cohort (12 OA-free and 72 hip OA-affected cartilage) and identified 179 DEGs between OA-free and OA-affected cartilage after correcting for multiple testing (P < 2.97 × 10-6). Pathway and network analyses found eight hub genes to be associated with hip OA (ASPN, COL1A2, MXRA5, P3H1, PCOLCE, SDC1, SPARC, and TLR2), which were all confirmed using qPCR in a validation cohort (36 OA-free and 62 hip OA-affected cartilage) (P < 6.25 × 10-3). Our data showed that dysregulation of extracellular matrix formation and imbalance in the proportion of collagen chains may contribute to the development of hip OA, and SDC1 could be a promising potential therapeutic target. These findings provided a better understanding of the molecular mechanisms for hip OA and may assist in developing targeted treatment strategies.
Insights
Researchers identified key genes involved in hip osteoarthritis (OA) by analyzing cartilage. Syndecan 1 (SDC1) emerged as a potential therapeutic target for this common joint disease.
Area of Science:
- Molecular biology
- Genomics
- Orthopedics
Background:
- Osteoarthritis (OA) is characterized by cartilage degradation.
- Hip OA significantly impacts patient mobility and quality of life.
- Identifying molecular targets is crucial for developing effective OA therapies.
Purpose of the Study:
- To identify and validate differentially expressed genes (DEGs) in human articular cartilage associated with hip OA.
- To uncover potential therapeutic targets for hip OA.
- To elucidate the molecular mechanisms underlying hip OA pathogenesis.
Main Methods:
- Transcriptomic profiling was performed on cartilage samples from OA-free and hip OA patients.
- Differentially expressed genes (DEGs) were identified using statistical analysis.
- Pathway and network analyses were conducted to identify hub genes.
- Quantitative real-time PCR (qPCR) was used to validate gene expression in an independent cohort.
Main Results:
- 179 DEGs were identified between OA-free and hip OA cartilage.
- Eight hub genes (ASPN, COL1A2, MXRA5, P3H1, PCOLCE, SDC1, SPARC, and TLR2) were associated with hip OA.
- Dysregulation of extracellular matrix formation and collagen chain imbalance were implicated in hip OA development.
- Syndecan 1 (SDC1) was confirmed as a promising potential therapeutic target.
Conclusions:
- The study identified key molecular players in hip OA pathogenesis.
- SDC1 represents a potential therapeutic target for hip OA.
- These findings enhance the understanding of hip OA molecular mechanisms and inform targeted treatment strategies.
